Heart and Vascula...
Follow
Find tag "hs-CRP"
28.7K views | +3 today
Heart and Vascular Health
Media, News & Topics on prevention, diagnosis & treatment of cardiovascular disease
Your new post is loading...
Your new post is loading...
Scooped by Seth Bilazarian, MD
Scoop.it!

Variability in High-Sensitivity C-Reactive Protein (CRP)

Variability in High-Sensitivity C-Reactive Protein (CRP) | Heart and Vascular Health | Scoop.it

C-reactive protein (CRP) is a marker of systemic inflammation and cardiovascular disease. CRP has been recommended as an adjunct screening tool to stratify cardiovascular risk in the general population. Evidence regarding within-person variability of CRP in the general population is limited. Short-term variability in CRP has important implications for its use & interpretation in clinical practice and research studies.  This study found significant short-term (approximately 2.5 weeks) within-person variability in CRP levels, particularly at high values. Approximately one-third of persons with elevated CRP levels were reclassified as having normal CRP levels after repeated testing. Our results are consistent with those of previous studies conducted in small selected populations (eg, patients with ischemic heart disease) or in which measurements were months or years apart.

more...
No comment yet.
Scooped by Seth Bilazarian, MD
Scoop.it!

Inflammation, Statin Therapy, and hsCRP: Initial Observations

Lecture slides form Dr. Paul Ridker at  ATVB 2011 – Inflammation, Immunity, and Atherosclerosis on Inflammation and Atherothrombosis: Where will new trials take us?

 

Great slide set for review of Inflammation, Statin Therapy, and hsCRP: Initial Observations

 

It discusses the as yet unanswered question can targeted Anti-Inflammatory Therapy Reduce Cardiovascular Risk?

 

Builds the case for why IL-1β inhibition is an attractive target based on experimental data and models and the current understanding of IL-1 and its potential roles in atherogenesis.  Also reviews the candidate therapy, Canakinumab (Ilaris, Novartis) being investigagted in the CANTOS trial.

 

Brief conclusion:

Is there evidence that individuals with elevated levels of inflammatory biomarkers are at high vascular risk even when other risk factors are acceptable? => YES
Is there evidence that individuals identified at increased risk due to inflammation benefit from a therapy they otherwise would not have received? => YES
Is there evidence that reducing inflammation will reduce vascular events? =>

WE NEED TO FIND OUT 

 

For patients with a prior histroy of heart attack (MI) interested in learning more about the CANTOS trial being conducted at PMA, under the direction of Dr. Sunny Srivistava in Haverhill see...

 

http://www.pmaonline.com/clinical-trials.htm

more...
No comment yet.
Scooped by Seth Bilazarian, MD
Scoop.it!

CRP tests for inflammation and gauges risk of cardiovascular disease

CRP tests for inflammation and gauges risk of cardiovascular disease | Heart and Vascular Health | Scoop.it

Blood test for high-sensitivity C-reactive protein (hs-CRP) —a marker for inflammation—is increasingly being used as a routine screening tool for patients who wonder if they are at risk of a heart attack or stroke.  Easily done at the same time as a cholesterol screening & covered by most insurance.  American Heart Association and American College of Cardiology both endorsed use of hs-CRP for "intermediate risk" individuals.

"We know that those with elevated hs-CRP are at high risk even if cholesterol levels are low, and that statin therapy can reduce the risk of heart attack and stroke in this group. While the JUPITER study showed inflammation contributes as much to cardiovascular risk as does high blood pressure or high cholesterol", Dr. Paul Ridker says "the core research question now is whether or not reducing inflammation per se will reduce that risk."

The ongoiing CANTOS trial will provide important information.  See my SCOOP IT at   http://www.scoop.it/t/heart-and-vascular-health/p/1559762525/inflammation-statin-therapy-and-hscrp-initial-observations ;

more...
No comment yet.